AIP
JAZZ icon

Ahrens Investment Partners’s Jazz Pharmaceuticals JAZZ Stock Holding History

Ahrens Investment Partners’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		$146 Buy
+1
New +$148 ﹤0.01% 994
2022
Q3 		– Sell
-1
Closed – – 551
2022
Q2 		$0 Hold
1
– – ﹤0.01% 1015
2022
Q1 		$0 Buy
+1
New +$145 ﹤0.01% 1075

Other funds holding JAZZ

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
PCM
Polaris Capital Management Boston, Massachusetts $1.06B AUM 40.82% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Ahrens Investment Partners's JAZZ Position: Q1 2023 in Review

Ahrens Investment Partners opened a new position in Jazz Pharmaceuticals (JAZZ) in Q1 2023: 1 share worth $146. The stake represents ﹤0.01% of the portfolio and ranks #994 among its holdings. This is a return to the name: Ahrens Investment Partners previously reported a position in JAZZ as recently as Q2 2022.

Ahrens Investment Partners first reported a position in JAZZ in Q1 2022 and has held it in 3 quarters since. 471 funds tracked by Wall St. Rank hold JAZZ as of Q1 2023.

  • Ahrens Investment Partners held 1 share of Jazz Pharmaceuticals worth $146 as of Q1 2023.
  • Jazz Pharmaceuticals was a new Ahrens Investment Partners position in Q1 2023.
  • Jazz Pharmaceuticals made up ﹤0.01% of Ahrens Investment Partners's portfolio in Q1 2023, its #994 holding.
  • Ahrens Investment Partners first reported a position in Jazz Pharmaceuticals in Q1 2022 and has held it in 3 quarters since.
  • 471 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2023.

Based on Ahrens Investment Partners's 13F filing for Q1 2023, filed 24 Apr 2023.